|
26 Nov 2020 |
Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)
|
|
25 Nov 2020 |
Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
|
|
25 Nov 2020 |
F-star Therapeutics Announces Clearance of Clinical Trial Application for FS222
|
|
25 Nov 2020 |
European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)
|
|
25 Nov 2020 |
Genmab Announces Enapotamab Vedotin Update
|
|
24 Nov 2020 |
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
|
|
23 Nov 2020 |
Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
|
|
23 Nov 2020 |
Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies
|
|
23 Nov 2020 |
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
|
|
22 Nov 2020 |
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
|
|
20 Nov 2020 |
Alvotech Announces That the U.S. FDA and EMA Have Accepted Regulatory Submissions for AVT02, a Proposed Biosimilar to HUMIRA® (adalimumab)
|
|
20 Nov 2020 |
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma
|
|
20 Nov 2020 |
SynOx Therapeutics raises €37M in Series A Financing
|
|
20 Nov 2020 |
Imfinzi approved in the US for less-frequent, fixed-dose use
|
|
20 Nov 2020 |
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
|
|
19 Nov 2020 |
PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314
|
|
19 Nov 2020 |
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
|
|
19 Nov 2020 |
Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat
|
|
18 Nov 2020 |
Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
|
|
17 Nov 2020 |
BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis
|
|
17 Nov 2020 |
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development
|
|
17 Nov 2020 |
Kiniksa Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis
|
|
17 Nov 2020 |
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
|
|
17 Nov 2020 |
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
|
|
17 Nov 2020 |
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
|
